Fatty acid binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon $\gamma$ pathway

Stephanie M Wood$^1$, Anthony J Gill$^2$, Alexander S Brodsky$^1$, Shaolei Lu$^1$, Kenneth Friedman$^1$, Galina Karashchuk$^1$, Kara Lombardo$^1$, Dongfang Yang$^1$, and Murray B Resnick$^1$

$^1$Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI, USA

$^2$Cancer Diagnosis and Pathology Research Group, Kolling Institute of Medical Research, Royal North Shore Hospital and University of Sydney, Sydney NSW 2006 Australia

Abstract

Fatty acid binding protein 1 (FABP1) is an intracellular protein responsible for transportation of long chain fatty acids. Aside from its functions in lipid metabolism and cellular differentiation, FABP1 also plays a role in inflammation through its interaction with peroxisome proliferator activated receptors. Previously, we compared expression of colonic epithelium genes in a subset of microsatellite instable (MSI) colorectal carcinomas (medullary carcinomas) to normal colonic mucosa and found that FABP1 expression was markedly decreased in the tumors. Further analysis of RNA expression in the colorectal subtypes and The Cancer Genome Atlas dataset found that FABP1 expression is decreased in the CMS1 subset of colorectal carcinomas, which is characterized by microsatellite instability. As microsatellite instable colorectal carcinomas are known for their robust immune response, we then aimed to link FABP1 to the immune microenvironment of microsatellite instable carcinomas. To confirm the gene expression results, we performed immunohistochemical analysis of a cohort of colorectal carcinomas. FABP1 was preferentially lost in microsatellite instable carcinomas (123/133, 93%) compared to microsatellite stable carcinomas (240/562, 43%, p <0.0001). In addition, higher numbers of tumor infiltrating lymphocytes were present in tumors with loss of FABP1 (p<0.0001). Decreased expression of the fatty acid storage and glucose regulator, peroxisome proliferator activated receptor $\gamma$ (PPAR$\gamma$), was associated with loss of FABP1 (p<0.0001). Colorectal cancer cell lines treated with interferon $\gamma$ exhibited decreased expression of FABP1. FABP1 expression was partially recovered with treatment of the cell lines with rosiglitazone, a PPAR$\gamma$ agonist. This study demonstrated that loss of FABP1 expression is associated with microsatellite instable carcinomas and that interferon $\gamma$ stimulation plays a role in this process via its interaction with PPAR$\gamma$. 

Disclosure/conflict of interest

The authors declare no conflict of interest.
Introduction

Colorectal carcinoma is a heterogeneous disease with multiple molecular pathways leading to tumorigenesis, many of which have prognostic and predictive significance. In routine practice colorectal carcinomas are assessed for microsatellite instability, which is characterized by deficiency of mismatch repair proteins and a hypermutator phenotype. Microsatellite instable (MSI) carcinomas typically have a better prognosis than microsatellite stable (MSS) carcinomas and are characterized by a robust immune microenvironment with increased tumor infiltrating lymphocytes and increased inflammatory cytokines (including interferon γ) (1–3) New classification systems in which MSI status plays a prominent role have been proposed to classify colorectal carcinomas based on gene-expression analysis in order to better predict prognosis and select patients for adjuvant therapy (3–5).

We initially aimed to examine genes differentially expressed in a subset of MSI tumors (medullary carcinomas) and found expression of the fatty acid binding protein 1 gene (FABP1) to be significantly decreased as compared to adjacent normal mucosa (6). FABP1, also called liver fatty acid binding protein (L-FABP) is an intracellular protein important in the transport of long chain fatty acids. FABP1 is a normal component of hepatocytes, enterocytes of the colon and small bowel, and is present to a lesser degree in tubular cells of the kidney and alveolar cells in the lung (7). It has been shown to be a marker of differentiation of colon enterocytes (8). The FABP family is involved in lipid metabolism, but also plays a role in the regulation of inflammation and cellular metabolism via interaction with peroxisome proliferator-activated receptors (PPARs) (9–14). FABP1 has been shown to directly interact with PPARγ in the nucleus to activate its downstream transcriptional targets, many of which are involved in cellular differentiation, apoptosis, and anti-inflammatory response (15–16). In addition to activating PPARγ, FABP1 is also a downstream transcriptional target of PPARγ, suggesting a delicate feedback loop involving inflammation and cellular proliferation (7,13,15).

FABP1 and PPARγ have been studied in various carcinomas including colorectal carcinoma. Loss of PPARγ in colorectal carcinoma has been described, with conflicting prognostic significance (17–19). FABP1 has been shown to be up-regulated in some carcinomas, such as carcinomas of the prostate and pancreas, while being lost in others (20,21). Loss of FABP1 has been described in colorectal carcinomas, though with conflicting prognostic data (5,20,22,23). However, FABP1 expression has not been evaluated with respect to MSI status. In this study we further characterize FABP1 expression in MSS vs MSI tumors and associate its expression with clinicopathologic features and PPARγ expression. We also performed in vitro studies to better clarify the relationship between FABP1 expression, immune pathways, and PPARγ.

Materials and Methods

Patients and samples

Archive formalin fixed paraffin embedded (FFPE) samples of colorectal carcinoma were collected by the Royal North Shore Hospital, St. Leonards Australia. Sample selection has
been described previously and is summarized here (24). Briefly, the computerized colorectal specimen database maintained by the Department of Anatomical Pathology at the Royal North Shore Hospital, Sydney, was searched to identify all cases of colorectal carcinomas that underwent non-endoluminal resection from 2007 to 2009. Cases other than colorectal adenocarcinoma and its variants were excluded, as were those carcinomas arising in the appendix. This database was current with all-cause survival data and all cases were staged according to the American Joint Committee on Cancer, 7th edition. A total of 722 colorectal carcinomas were analyzed: 576 MSS carcinomas and 133 MSI carcinomas (including 25 medullary carcinomas).

All-cause survival data in the database were derived from examination of hospital medical and pathology records, medical records from the surgeons’ private rooms, and publicly available death notices. Survival was calculated from the date of surgical resection to the last known date of contact or notification of death.

Tissue microarrays were constructed of two 1-mm cores from all colorectal carcinomas with available paraffin-embedded tissue from 2007–2009. Only adenocarcinomas were included in the study; neuroendocrine carcinomas and other malignancies were excluded.

**Gene Expression Analysis**

The medullary vs. normal tumor data was previously published (6) and the data are available in Gene Expression Omnibus (GSE76855). We evaluated the signals for the FABP family. Normalized HiSeq RNA-seq data for colorectal tumors from The Cancer Genome Atlas were downloaded from Firebrowse in September 2015 (6). Clinical data was downloaded from the The Cancer Genome Atlas data portal (https://tcga.data.nci.gov/tcga/dataAccessMatrix.htm, download in September 2015). Molecular subtypes (microsatellite instable-H, microsatellite instable-L and microsatellite stable) were acquired in The Cancer Genome Atlas clinical data. The authors’ annotation for the proposed molecular subtypes by Guinney et al. was used (4). Functional analyses were performed using Gene Set Enrichment Analysis (25). Fold change, t-tests, and multiple hypothesis tests were calculated in R version3.1.1.

**Immunohistochemistry**

Table 1 contains a summary of the immunohistochemical stains used. Briefly, stains for each antigen were performed on 5 μm paraffin sections of each tissue microarray masterblock. The panel included antibodies against CD3 (rabbit polyclonal, RTU, Dako, Carpinteria, CA), FABP1 (mouse monoclonal, 1:1000, Abcam, Cambridge, MA), and PPARγ (rabbit polyclonal, 1:50, Abcam). The stains were run on the Dako autostainer using the Envision Plus kit (Dako). Slides were counterstained with hematoxylin, dehydrated and coverslipped. Positive controls included normal colon (PPAR), normal tonsil (CD3), and normal liver (FABP).

**Immunohistochemical assessment and scoring**

Immunohistochemical stains for FABP1 and PPARγ were evaluated in tumor epithelium. CD3 was used to evaluate numbers of intratumoral infiltrating lymphocytes. For FABP1 and
PPARγ, epithelial staining was considered positive in cases with >10% moderate-to-intense staining in tumor epithelium. Staining was scored as negative for tumors with <10% moderate-to-intense staining. Tumors with less than moderate staining (including absence of staining) were included in the negative staining group. These cutoffs were determined and scored by a single observer (SW) to minimize interobserver variability. Intraepithelial lymphocytes positive for CD3 were manually counted and the counts per core were averaged for each tumor.

Cell culture

The human epithelial colorectal adenocarcinoma cell lines HT-29 (HTB-38) and Colo 205 (CCL-222) were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained in RPMI-1640 medium (Life Technologies) containing 2g/L D-Glucose and 2 mM glutamine and supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin. All cells were grown at 37 °C and 5% CO2. Cells were treated for 24 hours with 0.02% DMSO and 1% BSA, IFNγ (10ng/ml), rosiglitazone (10μM), or the combination of both. Interferon γ (IFNγ) and rosiglitazone were purchased from Sigma-Aldrich, Saint Louis, MO.

Quantitative real-time polymerase chain reaction

Total RNA was isolated from cells using RNeasy mini-kit (Qiagen, Valencia, CA) following the manufacturer’s instructions. The total RNA concentration and purity were determined using Nano drop spectrophotometer at 260 nm absorbance. Reverse transcription was conducted with Maxima First Strand cDNA Synthesis Kit for RT-qPCR (ThermoFisher Scientific, Houston, TX) on 1 μg of total RNA in a final reaction volume of 20 μL according to the manufacturer’s instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted in a final volume of 25 μL using SYBR Green/ROX qPCR Master Mix (2X) (ThermoFisher Scientific) for absolute gene quantification. All reactions were performed in duplicates. Values were normalized to actin and relative levels of mRNA expression were calculated by the $2^{-\Delta\Delta CT}$ method. The primer sequences used in this study are listed in Supplemental Table 1. Data are represented as mean or mean of log10 values ± standard deviation of 3 biological replicates.

Statistical Analysis

The chi-squared analysis was used to assess the immunohistochemical staining scores. One way variance analysis (ANOVA) and t-test were used for comparing lymphocyte counts among tumor types and between other characteristics. Cox proportional hazard analysis was used to evaluate the risk ratios in univariate and multivariate analysis. All tests were 2-sided with 0.05 as the threshold P value to be considered statistically significant. All analyses were performed using the SAS software, JMP Pro version 11.1 (SAS, Cary, NC, USA).

Results

Gene Expression Results

Of the 32 670 genes represented on the microarrays, 7429 were differentially expressed (p <0.05) between medullary carcinoma and adjacent histologically normal colonic mucosa in
all six cases. *FABP1* was decreased in medullary carcinoma vs normal colonic epithelium by 55 fold (p <0.001, FDR = 0.7). *PPARG* was decreased by 2 fold (p = 0.03, FDR = 0.2).

Amongst all tumors, *FABP1* expression was associated with *PPARG* expression in the Hiseq The Cancer Genome Atlas dataset (Rho 0.47, p <0.0001). *FABP1* and *PPARG* expression were also associated in MSI and MSS subgroups (Rho 0.47 and 0.48, respectively, p <0.0001 for both subgroups). *PPARA* expression was not statistically associated with *FABP1* expression in colon carcinomas in The Cancer Genome Atlas dataset (p = 0.2 for all tumors, p = 0.6 for MSS tumors, and p = 0.1 for MSI tumors).

**Consensus Molecular Subtype comparison**

Four consensus molecular subtypes of colorectal carcinomas were recently proposed (4). We assessed the expression of *FABP1* and *PPARG* in these subtypes in The Cancer Genome Atlas RNA-seq data. Two-hundred thirty three colorectal carcinomas with known CMS group classification were compared for *FABP1* and *PPARG* expression. The CMS1 carcinomas had decreased *FABP1* and *PPARG* expression when compared to the other CMS groups (CMS2, CMS3, CMS4) and carcinomas of unknown CMS group (Figure 1). CMS1 is enriched for MSI cases and high immune cell infiltration. These observations show that expression of *FABP1* and *PPARG* is decreased in tumors with MSI.

**Clinicopathologic features**

The clinicopathologic features of patients and their tumors included in the tissue microarray are summarized in Table 2. Tumor site and grade were unavailable for 2 and 3 patients, respectively. Tumor size was unavailable for two patients. The average age at time of surgery was 72 years (77 years for patients with MSI tumors and 71 year for MSS tumors). A majority of the patients with MSI tumors were female (72% female) compared to MSS tumors (48% female, p <0.0001), and MSI tumors were more often located in the right colon (69% right sided) when compared to MSS tumors (31% right sided, p <0.0001). MSI tumors presented at a lower stage (70% in stage I–II) than MSS tumors (47% stage I–II, p <0.0001), though on average MSI tumors were larger in size (5.1 cm vs 4.2 cm, p <0.0001). MSI tumors were less likely to have lymphovascular invasion (present in 37% of MSI vs 49% of MSS tumors, p 0.01). Lymph node metastasis was more common in MSS tumors (49% vs 29%, p < 0.0001).

**FABP1 protein expression and correlation with other clinicopathologic features**

Based on the gene expression results which found *FABP1* to be decreased in medullary carcinomas (a subset of microsatellite instable carcinomas), we decided to test a panel of colorectal carcinomas for protein FABP1 expression via immunohistochemistry. FABP1 stained in a cytoplasmic and nuclear pattern in tumor and normal colorectal epithelial cells (Figure 2). Staining in normal epithelium was confined to the surface epithelial cells, similar to previously reported staining patterns (11). There was loss of expression of FABP1 in 52% of all tumors tested (Figure 3). The majority of MSI tumors showed loss of FABP1 (93%) while only 43% of MSS tumors had loss of FABP1 staining (p<0.0001, Figure 3). FABP1 was lost in 96% of medullary carcinomas, compared to 59% of non-medullary carcinomas (including non-medullary MSI carcinomas and MSS carcinomas, p = 0.0003)
Loss of FABP1 expression in all colorectal carcinomas associated significantly with older age (p<0.0001), right sided location of tumor (p<0.0001), and higher grade (p<0.0001, Table 3). Within the MSI tumors, loss of FABP1 expression associated significantly with right sided location (p = 0.001). Within the MSS tumors, loss of FABP1 expression associated significantly with older age (p = 0.003, Table 3).

PPARγ expression and correlation with other clinicopathologic features

We hypothesized that FABP1 loss may be linked to microsatellite instable tumors via inflammatory pathways that include the PPARγ protein (9–13). Therefore, we tested for PPARγ expression in our colorectal carcinoma cohort via immunohistochemistry. PPARγ stained in a nuclear pattern in tumor and normal colorectal epithelial cells. Loss of PPARγ was seen in 11% of all tumors and was more common in MSI over MSS tumors (22% and 8.8% respectively, p <0.0001) (Figure 3).

Loss of PPARγ in all colorectal carcinomas was associated with right sided location (p = 0.03) and lower stage (p = 0.04, Table 3). Within the MSI and MSS tumors, PPARγ did not significantly associate with clinicopathologic features.

CD3 tumor infiltrating lymphocytes and correlation with other clinicopathologic features

Because our hypothesis linked FABP1 loss to MSI carcinomas via immune pathways, we decided to evaluate the number of tumor infiltrating lymphocytes in our cohort. CD3 immunohistochemistry was utilized to count intratumoral lymphocytes. As expected, MSI tumors demonstrated higher average tumor infiltrating lymphocytes than MSS tumors (151 and 35 respectively, p <0.0001) (Figure 5).

Among all colorectal carcinomas, higher numbers of tumor infiltrating lymphocytes associated significantly with right-sided location (p<0.0001), absence of lymphovascular invasion (p = 0.04), lower stage (p<0.0001), and high grade (p<0.0001, Table 4).

Within MSI tumors, higher tumor infiltrating lymphocytes associated significantly with high grade (p = 0.02). In MSS tumors, higher numbers of tumor infiltrating lymphocytes associated significantly with absence of lymphovascular invasion (p = 0.0005), and lower stage (p<0.0001).

Correlation of FABP1 with PPARγ and tumor infiltrating lymphocytes

We hypothesized that loss of FABP1 was due to increased inflammation associated with MSI tumors. We therefore expected FABP1 to be decreased in tumors with increased tumor infiltrating lymphocytes. As a part of the proposed pathway, we expected decreased FABP1 to be associated with decreased PPARγ. Our data showed that in all colorectal carcinomas, loss of expression of FABP1 significantly associated with loss of PPARγ (p<0.0001) and increased tumor infiltrating lymphocytes (p<0.0001, Figures 4, 5).

Within MSI colorectal carcinomas, loss of FABP1 expression significantly associated with loss of PPARγ (p = 0.03). Though not statistically significant, MSI tumors with loss of FABP1 showed increased tumor infiltrating lymphocytes (74 in FABP positive MSI tumors vs 157 in FABP negative MSI tumors, p = 0.2). Likely, the lack of statistical significance is
due to the low numbers of MSI tumors that are also FABP positive. Within MSS colorectal carcinomas, loss of FABP1 expression significantly associated with loss of PPARγ (p = 0.02) expression.

**IFNγ down-regulates and stimulation of PPARγ up-regulates FABP1 Expression**

Increased tumor infiltrating lymphocytes in MSI tumors is associated with the IFNγ pathway (2). In addition, interferon gamma response was significantly associated with FABP1 expression in The Cancer Genome Atlas database colorectal tumor data (6). To test if interferon gamma could repress FABP1 expression, two colorectal cancer cell lines were treated with IFNγ. RT-qPCR analysis of the RNA demonstrated a significant decrease in FABP1 mRNA expression in both lines. Rosiglitazone, a PPARγ agonist, reversed this inhibition and up-regulated FABP1 expression. IDO and FAS, known targets of IFNγ, served as positive controls (26,27) (Figure 6). IFNγ did not consistently induce an expression change in PPARγ in either cell line.

**Survival data**

FABP1 and PPARγ expression did not correlate with survival. In a multivariate analysis, higher stage (HR = 2.1, 95% CI 1.6–2.9, p = <0.0001) and high grade (HR = 1.8, 95% CI 1.2–2.4, p = 0.002) were associated with worse survival while the presence of microsatellite instability was associated with improved survival (HR = 0.5, 95% CI 0.3–0.8, p = 0.005), consistent with past findings (28).

**Discussion**

Colorectal carcinomas are a biologically diverse group of carcinomas with microsatellite instability playing an important prognostic and predictive role. MSI tumors exhibit improved survival over MSS carcinomas, which is thought to be related to the increased inflammatory response to these tumors (2,28). Recently, gene-expression studies have proposed molecular classifications of colorectal carcinomas in order to better predict prognosis and response to adjuvant therapy. However, these multi-gene classification systems are currently not well suited for clinical practice (3,4). Single biomarkers or small panels of biomarkers are better suited for clinical utility, if they exist.

In a previous study, we examined a subset of microsatellite instable colorectal carcinomas (medullary carcinomas) to identify genes that were differentially expressed when compared to normal colon epithelium. Many immunoregulatory genes activated by IFNγ were upregulated in medullary colorectal carcinomas (6). Of the genes that were differentially expressed or lost in medullary carcinoma, FABP1 was shown to be decreased by 55 fold when compared to normal colon epithelium of the same patient. In this study, we examined a larger cohort of colorectal carcinomas and showed a correlation between decreased FABP1 expression (via immunohistochemistry) and MSI tumors. This finding was supported by the finding decreased FABP1 expression in the CMS1 subgroup of colorectal carcinomas, which is characterized by microsatellite instability. Since loss of FABP1 is associated with MSI colorectal carcinomas, it is not surprising that we also demonstrated decreased FABP1 to be associated with increased tumor infiltrating lymphocytes in all cases (30–32). A similar...
trend was noted amongst MSI tumors, though this result was not statistically significant, likely due to the low numbers of FABP1 positive MSI cases. Interestingly, there was no correlation between increased tumor lymphocytes with FABP1 loss in the MSS cases. Although it is not clear whether the increase in tumor infiltrating lymphocytes are directly associated with decreased FABP1 expression in the MSI population, one possible mechanism involves interferon gamma (IFNγ) and the PPARγ pathway as it is well described that tumor infiltrating lymphocytes in MSI colorectal carcinomas are associated with upregulation of the IFNγ pathway (2,6). IFNγ expression is increased in MSI tumors when compared to MSS tumors (2). The loss of FABP1 in the MSS tumors likely does not share the same inflammatory pathway.

FABP1 has been linked to the regulation of inflammatory states via its interaction with PPARs, including PPARα and PPARγ (9–13). PPARs are nuclear transcription factors whose downstream effects manage lipid metabolism, inflammation, and cellular metabolism (13,16,32–35). While FABP1 has been shown to interact with both PPARα and PPARγ in colorectal epithelium, PPARα expression was not statistically associated with FABP1 expression in colon carcinomas in The Cancer Genome Atlas dataset, whereas PPARγ expression was associated with FABP1 expression. Also, prior studies have linked inactivation of PPARγ with high inflammatory states (34). Therefore, we concentrated on the association of FABP1 and PPARγ.

Because of its role in cellular metabolism including apoptosis, cellular proliferation, and angiogenesis, PPARγ has been of interest in many carcinomas (17–19,22). Activation of PPARγ appears to promote apoptosis and cellular differentiation, inhibit angiogenesis, and decrease cellular proliferation (17). Based on these properties it would seem that increased PPARγ and/or PPARγ agonists would have anti-tumor effects. However, multiple studies have shown the opposite: increased PPARγ/activation of PPARγ actually promote carcinogenesis. Two studies involving mice with germ-line APC mutations have shown that mice treated with PPARγ agonists develop more colorectal carcinomas than those without PPARγ agonists. Similarly, mice modified with high levels of PPARγ in breast tissue are more likely to develop breast carcinoma (15,18,36,37). There have been conflicting results in retrospective studies of PPARγ in human colorectal carcinoma. At least one study has shown an improved survival in patients with PPARγ positive colorectal carcinomas in multivariate analysis (18), while others have shown no association with prognosis (36,37). PPARγ has been studied in other carcinomas, also with conflicting results (15). It may be that there is a balance between PPARγ’s anti-proliferative effects and its anti-inflammatory effects, and the tumor microenvironment may play a role in establishing PPARγ in a tumor suppressor or oncogenic role.

Not only does activation of PPARγ have downstream effects on inflammation, but it is also negatively regulated by pro-inflammatory cytokines (specifically IFNγ and TNFα). PPARγ is bound to RXR in the nucleus in the absence of ligand. The PPARγ-RXR heterodimer is not transcriptionally active, and instead acts as an inhibitor when bound to DNA. In the presence of IFNγ and TNFα, PPARγ’s effects are inhibited both by decreased expression of PPARγ and by stabilization of the PPARγ-RXR heterodimer (33). FABP1 is an important part of the PPARγ pathway. FABP1 (with attached fatty acid ligand) has been localized to
the nucleus, where it has been shown to directly interact with PPARs (including PPARγ) (14,16). This in turn activates PPARγ and results in expression of downstream transcription targets (including anti-proliferation and anti-inflammatory genes). Not only can FABP1 activate PPARγ, there is also evidence that one of the downstream targets of PPARγ is actually FABP1 itself, forming a feedback loop (7,13). In vivo, this feedback loop is thought to decrease transcription of FABP1 when its ligands (long chain fatty acids) are scarce, and increase FABP1 during an abundance of ligand. Disruption of this balance (via a robust immune response/increased IFNγ) may lead constitutively inactive PPARγ and decreased FABP1.

We proposed that the high immune response environment of MSI colorectal carcinomas may inhibit PPARγ via production of IFNγ which leads to decreased transcription of FABP1. The decreased FABP1 further decreases activation of PPARγ through the feedback loop described above. Via immunohistochemistry, we showed that PPARγ expression is more likely to be decreased in colorectal carcinomas with decreased FABP1. Interestingly, PPARγ loss did not appear to associate with increased tumor infiltrating lymphocytes. However, IFNγ inhibits PPARγ’s transcriptional function via multiple mechanisms, including inactivation (33); therefore it is possible that the PPARγ present in the tumors is inactive. To further corroborate the link between IFNγ, PPARγ, and FABP1 we performed in-vitro studies using FABP1-expressing colorectal carcinoma cell lines. Cells treated with IFNγ had decreased FABP1 expression when compared to the control. Though this suggests decreased FABP1 is due to the presence of IFNγ, this does not prove that the pathway involves PPARγ. In fact, PPARγ was not decreased in the colorectal carcinoma cell lines when treated with IFNγ. However, PPARγ has been shown to be present but inactive in the presence of IFNγ in macrophages (33). To test our hypothesis that PPARγ plays a role in this pathway, we treated the colorectal cell line with a PPARγ antagonist, rosiglitazone. In the cells treated with IFNγ and rosiglitazone, there was a modest recovery of FABP1 expression (as compared to cells treated with IFNγ alone). These results support the hypothesis that the immune microenvironment of MSI tumors disrupts the PPARγ/FABP1 feedback loop, leading to decreased PPARγ function and loss of FABP1 expression.

Based on FABP1’s downstream effects including cellular differentiation and anti-proliferation (via its interaction with PPARγ), loss of FABP1 in colorectal carcinomas would be expected to result in de-differentiated tumors and worse prognosis. On the other hand, FABP1 has also been shown to have antioxidant properties by reducing reactive oxygen species (7,38). Thus, decreased FABP1 could lead to increased reactive oxygen species and increased tumor cell death. Prior studies have searched for a link between FABP1 and prognosis, though results have been conflicting. Yamazaki et al showed loss of FABP1 in liver metastasis from colorectal carcinomas to be associated with decreased survival (23) while Lyall et al found that decreased FABP1 yielded better survival. However, in their same data set, their “very poor prognosis” subgroup of colorectal carcinomas was characterized by low FABP1 expression (5). In another study, loss of FABP1 in colorectal carcinomas was associated with increased lymph node metastasis (22). FABP1 expression is particularly low in the CMS1 group in the recently proposed molecular subtypes, and CMS1 is among the better prognostic groups, compared to the clearly poor prognostic group CMS4. The link between FABP1 and microsatellite instability (through inflammatory
cytokines and PPARγ) may help explain the improved prognosis of MSI colorectal carcinomas via FABP1’s antioxidant properties.

FABP1 expression in colorectal carcinomas did not appear to correlate with survival in our cohort, however, there were some limitations of our survival data. Many patients had only a short length of follow-up after surgery, and patient disease status (alive without disease, alive with disease, deceased) was unavailable for many. We therefore used date of last follow up as an end point for patients with unknown data. This likely inhibited the strength of our survival data.

In conclusion, we found that FABP1 is decreased in MSI colorectal carcinomas opposed to MSS colorectal carcinomas. We provide evidence that FABP1 loss is tied to inhibition of PPARγ by the immune microenvironment of MSI colorectal carcinomas. Though we were unable to relate FABP1 expression to prognostic significance in our cohort, we present a possible link between FABP1 expression and MSI colon cancers via a robust immune response and PPARγ. This study provides additional evidence to the complex relationship between metabolic and immune pathways in carcinogenesis.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

Research reported in this publication was supported by the Molecular Pathology Core of the COBRE Center for Cancer Research Development, funded by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM103421.

**Grants:** Center for Cancer Research Development, funded by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM103421

**References**

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61:759–767. [PubMed: 2188735]
2. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015; 5:43–51. [PubMed: 25358689]
3. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015; 148:77–87. [PubMed: 25280443]
4. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21:1350–6. [PubMed: 26457759]
5. Lyall MS, Dundas SR, Curran S, et al. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res. 2006; 12:1184–91. [PubMed: 16489072]
6. Friedman K, Brodsky AS, Lu S, et al. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod Pathol. 2016; 29:528–41. [PubMed: 26965581]
7. Wang G, Bonkovsky HL, de Lemos A, et al. Recent insights into the biological functions of liver fatty acid binding protein 1. J Lipid Res. 2015; 56:2238–47. [PubMed: 26443794]
8. Trotter PJ, Storch J. Fatty acid uptake and metabolism in a human intestinal cell line (Caco-2): comparison of apical and basolateral incubation. J Lipid Res. 1991; 32:293–304. [PubMed: 2066664]
9. Boiteux G, Lascombe I, Roche E, et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer. 2009; 124:1820–8. [PubMed: 19115207]

10. Gajda AM, Storch J. Enterocyte fatty acid-binding proteins (FABPs): different functions of liver and intestinal FABPs in the intestine. Prostaglandins Leukot Essent Fatty Acids. 2015; 93:9–16. [PubMed: 25458898]

11. Levy E, Ménard D, Delvin E, et al. Localization, function and regulation of the two intestinal fatty acid-binding protein types. Histochem Cell Biol. 2009; 132:351–67. [PubMed: 19499240]

12. Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr. 2008; 28:73–95. [PubMed: 18435590]

13. Varga T, Czirmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta. 2011; 1812:1007–22. [PubMed: 21382489]

14. Velkov T. Interactions between Human Liver Fatty Acid Binding Protein and Peroxisome Proliferator Activated Receptor Selective Drugs. PPAR Res. 2013; 2013:938401. [PubMed: 23476633]

15. Wang T, Xu J, Yu X, et al. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol. 2006; 58:1–14. [PubMed: 16388966]

16. Wolfrum C, Borrmann CM, Borchers T, et al. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha – and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A. 2001; 98:2323–8. [PubMed: 11226238]

17. Gustafsson A, Hansson E, Kressner U, et al. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer. 2007; 121:232–40. [PubMed: 17290397]

18. Ogino S, Shima K, Baba Y, et al. Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology. 2009; 136:1242–50. [PubMed: 19186181]

19. Theocharis S, Giaginis C, Parasi A, et al. Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients’ survival. Dig Dis Sci. 2007; 52:2305–11. [PubMed: 17393321]

20. Lawrie LC, Dundas SR, Curran S, et al. Liver fatty acid binding protein expression in colorectal neoplasia. Br J Cancer. 2004; 90:1955–60. [PubMed: 15138477]

21. Sharaf RN, Butte AJ, Montgomery KD, et al. Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes. BMC Gastroenterol. 2011; 11:5. [PubMed: 21251264]

22. Pei H, Zhu H, Zeng S, et al. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J Proteome Res. 2007; 6:2495–501. [PubMed: 17542627]

23. Yamazaki T, Kanda T, Sakai Y, et al. Liver fatty acid-binding protein is a new prognostic factor for hepatic resection of colorectal cancer metastases. J Surg Oncol. 1999; 72:83–7. [PubMed: 10518104]

24. Chou A, Toon CW, Clarkson A, et al. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol. 2014; 45:1679–1703.

25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545–50. [PubMed: 16199517]

26. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006; 12:1144–51. [PubMed: 16489067]

27. Schwartzberg LS, Petak I, Stewart C, et al. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. Clin Cancer Res. 2002; 8:2488–98. [PubMed: 12171874]
28. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993; 260:816–9. [PubMed: 8484122]
29. Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001; 158:527–535. [PubMed: 11159189]
30. Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015; 1:1319–1323. [PubMed: 26181000]
31. Tougeron D, Fauquembergue E, Rouquette A, et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol. 2009; 22:1186–1195. [PubMed: 19503063]
32. Hughes ML, Liu B, Halls ML, et al. Fatty Acid-binding Proteins 1 and 2 Differentially Modulate the Activation of Peroxisome Proliferator-activated Receptor α in a Ligand-selective Manner. J Biol Chem. 2015; 290:13895–906. [PubMed: 25847235]
33. Nagy ZS, Czimmerer Z, Szanto A, et al. Pro-inflammatory cytokines negatively regulate PPARγ mediated gene expression in both human and murine macrophages via multiple mechanisms. Immunobiology. 2013; 218:1336–44. [PubMed: 23870825]
34. Schachtrup C, Emmler T, Bleck B, et al. Functional analysis of peroxisome proliferator-responsive element motifs in genes of fatty acid-binding proteins. Biochem J. 2004; 382:239–45. [PubMed: 15130092]
35. Tan NS, Shaw NS, Vinckenbosch N, et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol. 2002; 22:5114–27. Erratum in: Mol Cell Biol 2002, 22:6318. [PubMed: 12077340]
36. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 1998; 4:1053–7. [PubMed: 9734399]
37. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998; 4:1058–61. [PubMed: 9734400]
38. Yan J, Gong Y, She YM, Wang G, et al. Molecular mechanism of recombinant liver fatty acid binding protein’s antioxidant activity. J Lipid Res. 2009; 50:2445–54. [PubMed: 19474456]
Figure 1.

*FABP1* and *PPARγ* expression in The Cancer Genome Atlas HiSeq colorectal carcinoma data was distributed across the pre-assigned classification of colorectal carcinoma subtypes according to Guinney et al (3). *FABP1* and *PPARγ* show decreased expression in the microsatellite instability immune subgroup (CMS1) when compared to the other categories. UNK = unknown subtype
Figure 2.
Representative immunohistochemistry staining of normal colonic epithelium, positive staining colorectal carcinomas, and negative staining colorectal carcinomas for FABP1 and PPARγ. Left column, normal colonic epithelium; middle column, negative staining pattern; right column, positive staining pattern.
Figure 3.
FABP1 expression is decreased in MSI colorectal carcinomas over MSS colorectal carcinomas. Overall expression and paired data for immunohistochemistry expression results in MSI compared to MSS colorectal carcinomas. **statistically highly significant as p < 0.001.
Figure 4.
Comparison of staining patterns in colorectal carcinomas. Percentage of PPARγ negative (PPARg −) and PPARγ positive (PPARg +) staining in tumors as compared to their FABP staining (in all cases, MSI cases, and MSS cases). **statistically highly significant as p < 0.05.
Figure 5.
Average number of tumor infiltrating lymphocytes in colorectal carcinomas compared to their staining pattern in all cases, MSS cases, and MSI cases. **statistically significant as $p < 0.05$. 
A

Interferon Gamma Response Hallmark

Enrichment Score (ES)

NES=-2.7
FDR<0.000

Associated with
High FABP1 Expression

Associated with
Low FABP1 Expression
Figure 6.
Interferon γ inhibits FABP1 expression in colorectal cancer cell lines. HT-29 and Colo205 cells were treated for 24 hours with vehicle or IFNγ (10ng/ml), or rosiglitazone (10μM), or with the combination of both as indicated. (A): FABP1 mRNA expression is negatively correlated with interferon gamma response. A rank list of the Pearson correlated transcripts in the colorectal carcinoma data from The Cancer Genome Atlas was submitted to Gene Set Enrichment Analysis as a pre-rank file. The Interferon Gamma Response Hallmark was the top ranked negatively associated gene set. The FABP1 (B) and controls (C,D) mRNA expression level were determined by qRT-PCR upon treatment. The results are expressed as a fold change relative to vehicle treated cells. *, statistically significant p < 0.05 and
**statistically highly significant as p < 0.001. Error bars represent standard deviation. Columns represent mean of three experiments.
Table 1

| Antibody | Vendor | Host          | Antigen Retrieval       | Dilution | Detection Method          |
|----------|--------|---------------|-------------------------|----------|---------------------------|
| **PPARγ**| Abcam  | Rabbit Polyclonal | EDTA pH 9 Microwave 120°C, 10 min | 1:50     | Dako Envision + Kit       |
| **CD3**  | Dako   | Rabbit Polyclonal | EDTA pH 9 Dako PTLink 97°C, 20 min | RTU      | Dako Envision FLEX Autostainer |
| **FABP1**| Abcam  | Mouse Monoclonal Clone 2G4 | EDTA pH 9 Dako PTLink 97°C, 20 min | 1:1000   | Dako Envision FLEX Autostainer |
Clinicopathologic features of study population.

| Clinicopathologic features       | All Tumors (695) | MSI (n=133) | MSS (n=562) | p value |
|----------------------------------|------------------|-------------|-------------|---------|
| Age at surgery                   |                  |             |             |         |
| mean                             | 72 (47%)         | 77 (59%)    | 71 (49%)    | <0.0001 |
| range                            | 33–99 (28%)      | 41–97 (23%) | 33–99 (23%) |         |
| Sex                              |                  |             |             |         |
| male                             | 330 (47%)        | 37 (28%)    | 293 (52%)   | <0.0001 |
| female                           | 365 (53%)        | 96 (72%)    | 269 (48%)   |         |
| Location                         |                  |             |             |         |
| right                            | 263 (38%)        | 91 (69%)    | 172 (31%)   | <0.0001 |
| transverse                       | 66 (10%)         | 30 (23%)    | 36 (6%)     |         |
| left                             | 364 (52%)        | 11 (8%)     | 353 (63%)   |         |
| Grade                            |                  |             |             |         |
| low                              | 549 (79%)        | 78 (59%)    | 471 (84%)   | <0.0001 |
| high                             | 143 (21%)        | 54 (41%)    | 89 (16%)    |         |
| Stage                            |                  |             |             |         |
| I                                | 112 (16%)        | 16 (12%)    | 96 (17%)    | <0.0001 |
| II                               | 245 (35%)        | 77 (58%)    | 168 (30%)   |         |
| III                              | 312 (45%)        | 39 (29%)    | 273 (49%)   |         |
| IV                               | 26 (4%)          | 1 (1%)      | 25 (4%)     |         |
| Tumor size                       | 4.4 cm           | 5.1         | 4.2         | <0.0001 |
| Lymphovascular invasion          |                  |             |             |         |
| present                          | 325 (47%)        | 49 (37%)    | 276 (49%)   | 0.01    |
| absent                           | 370 (53%)        | 84 (63%)    | 286 (51%)   |         |
| Lymph node metastasis            |                  |             |             |         |
| present                          | 313 (45%)        | 39 (29%)    | 274 (49%)   | <0.0001 |
| absent                           | 382 (55%)        | 94 (71%)    | 288 (51%)   |         |

1 Site missing for 2 cases (one MSI case and one MSS case)

2 Grade missing for 3 cases (one MSI case and two MSS cases)
Table 3

Clinicopathologic features in relation to staining characteristics of colorectal carcinomas in all cases, MSI cases, and MSS cases.

|          | Age | Gender | Location | Lymphovascular invasion | Stage (%) | Grade |
|----------|-----|--------|----------|--------------------------|-----------|-------|
|          | Mean age | p value | Female (%) | p value | Right (%) | p value | Present (%) | p value | 1 | 2 | 3 | 4 | p value | High (%) | p value |
| FABP     | All cases | + | 70 | <0.0001 | 50 | 0.2 | 25 | <0.0001 | 51 | 0.06 | 15 | 31 | 50 | 4 | 0.09 | 14 | <0.0001 |
|          | − | 74 | 55 | 49 | 44 | 0.06 | 17 | 39 | 41 | 4 | 27 |
|          | MSI | + | 72 | 0.2 | 89 | 0.2 | 56 | 0.001 | 38 | 0.6 | 0 | 67 | 33 | 0 | 0.5 | 6 | 0.6 |
|          | − | 77 | 71 | 70 | 30 | 0.2 | 13 | 57 | 29 | 1 | 8 |
|          | MSS | + | 70 | 0.003 | 49 | 0.7 | 25 | 0.2 | 47 | 0.3 | 16 | 30 | 50 | 4 | 0.6 | 13 | 0.07 |
|          | − | 73 | 57 | 38 | 52 | 0.7 | 19 | 30 | 46 | 5 | 19 |
| PPARγ    | All cases | + | 72 | 0.1 | 53 | 0.8 | 36 | 0.03 | 47 | 1.0 | 17 | 33 | 46 | 4 | 0.04 | 20 | 0.08 |
|          | − | 74 | 51 | 51 | 47 | 0.4 | 10 | 50 | 37 | 3 | 29 |
|          | MSI | + | 76 | 0.8 | 73 | 0.7 | 68 | 0.7 | 34 | 0.7 | 13 | 56 | 32 | 0 | 0.2 | 40 | 0.6 |
|          | − | 77 | 69 | 72 | 38 | 0.2 | 10 | 66 | 21 | 3 | 45 |
|          | MSS | + | 71 | 0.3 | 49 | 0.3 | 30 | 0.4 | 55 | 0.4 | 18 | 29 | 49 | 5 | 0.2 | 16 | 0.6 |
|          | − | 73 | 41 | 39 | 49 | 0.4 | 10 | 41 | 47 | 2 | 19 |
### Table 4

Average count of tumor infiltrating lymphocytes in relation to clinicopathologic features. F=female, M=male, L=left, R=right

|                       | Gender | Location | LVI | Stage | Grade |
|-----------------------|--------|----------|-----|-------|-------|
|                       | F      | M        | p value | R     | L    | p value | Present | Absent | p value | 1    | 2    | 3    | 4    | p value | Low | High | p value |
| Tumor infiltrating lymphocytes (average) | All cases | 64 | 49 | 0.06 | 78 | 40 | <0.0001 | 49 | 65 | 0.04 | 78 | 75 | 37 | 36 | <0.0001 | 47 | 90 | <0.0001 |
|                       | MSI    | 135 | 192 | 0.1 | 205 | 154 | 0.4 | 163 | 143 | 0.6 | 206 | 152 | 127 | 95 | 0.5 | 118 | 191 | 0.02 |
|                       | MSS    | 39 | 21 | 0.2 | 38 | 34 | 0.5 | 28 | 42 | 0.005 | 57 | 41 | 24 | 34 | <0.0001 | 35 | 28 | 0.3 |